Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation

Steve N. Caritis; Shringi Sharma; Raman Venkataramanan; Gary D. Hankins; Menachem Miodovnik; Mary F. Hebert; Jason G. Umans; Thomas Benedetti; Donald Mattison; Anne Zajicek; Dawn Fischer; Aimee Jackson

doi:10.1016/j.ajog.2012.08.015

Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation

Steve N. Caritis, Shringi Sharma, Raman Venkataramanan, Gary D. Hankins, Menachem Miodovnik, Mary F. Hebert, Jason G. Umans, Thomas Benedetti, Donald Mattison, Anne Zajicek, Dawn Fischer, Aimee Jackson

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Abstract

Objective: The purpose of this study was to estimate pharmacokinetic parameters and to evaluate placental transport of 17-hydroxyprogesterone caproate (17-OHPC) in singleton gestation. Study Design: Sixty-one women who received weekly injections of 17-OHPC underwent 2 pharmacokinetic studies at 20 + 0 to 24 + 6 weeks' gestation (study 1) and 31 + 0 to 34 + 6 weeks' gestation (study 2); daily blood samples were obtained between injections. In 18 women, blood samples were obtained over a 28-day period beyond the last injection (extended study). Maternal and/or cord blood were obtained at delivery. Results: The half-life (median ± SD) of 17-OHPC was 16.2 ± 6 days. Concentrations of 17-OHPC were higher during study 2 than during study 1. Body mass index affected maternal 17-OHPC concentrations. Cord:maternal 17-OHPC concentration ratios averaged 0.2; 17-OHPC was detectible in cord plasma 44 days after the last maternal injection. Conclusion: The apparent half-life of 17-OHPC is long, and pharmacokinetic parameters vary widely between subjects and are affected by maternal body mass index. The drug crosses the placental barrier.

Original language	English (US)
Pages (from-to)	398.e1-398.e8
Journal	American journal of obstetrics and gynecology
Volume	207
Issue number	5
DOIs	https://doi.org/10.1016/j.ajog.2012.08.015
State	Published - Nov 2012
Externally published	Yes

Keywords

cord blood
pharmacokinetics
placenta
preterm birth

ASJC Scopus subject areas

Obstetrics and Gynecology

Access to Document

10.1016/j.ajog.2012.08.015

Cite this

Caritis, S. N., Sharma, S., Venkataramanan, R., Hankins, G. D., Miodovnik, M., Hebert, M. F., Umans, J. G., Benedetti, T., Mattison, D., Zajicek, A., Fischer, D., & Jackson, A. (2012). Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation. American journal of obstetrics and gynecology, 207(5), 398.e1-398.e8. https://doi.org/10.1016/j.ajog.2012.08.015

Caritis, SN, Sharma, S, Venkataramanan, R, Hankins, GD, Miodovnik, M, Hebert, MF, Umans, JG, Benedetti, T, Mattison, D, Zajicek, A, Fischer, D & Jackson, A 2012, 'Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation', American journal of obstetrics and gynecology, vol. 207, no. 5, pp. 398.e1-398.e8. https://doi.org/10.1016/j.ajog.2012.08.015

@article{ab07c42737fc4548bb0f90c42c104229,

title = "Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation",

abstract = "Objective: The purpose of this study was to estimate pharmacokinetic parameters and to evaluate placental transport of 17-hydroxyprogesterone caproate (17-OHPC) in singleton gestation. Study Design: Sixty-one women who received weekly injections of 17-OHPC underwent 2 pharmacokinetic studies at 20 + 0 to 24 + 6 weeks' gestation (study 1) and 31 + 0 to 34 + 6 weeks' gestation (study 2); daily blood samples were obtained between injections. In 18 women, blood samples were obtained over a 28-day period beyond the last injection (extended study). Maternal and/or cord blood were obtained at delivery. Results: The half-life (median ± SD) of 17-OHPC was 16.2 ± 6 days. Concentrations of 17-OHPC were higher during study 2 than during study 1. Body mass index affected maternal 17-OHPC concentrations. Cord:maternal 17-OHPC concentration ratios averaged 0.2; 17-OHPC was detectible in cord plasma 44 days after the last maternal injection. Conclusion: The apparent half-life of 17-OHPC is long, and pharmacokinetic parameters vary widely between subjects and are affected by maternal body mass index. The drug crosses the placental barrier.",

keywords = "cord blood, pharmacokinetics, placenta, preterm birth",

author = "Caritis, {Steve N.} and Shringi Sharma and Raman Venkataramanan and Hankins, {Gary D.} and Menachem Miodovnik and Hebert, {Mary F.} and Umans, {Jason G.} and Thomas Benedetti and Donald Mattison and Anne Zajicek and Dawn Fischer and Aimee Jackson",

year = "2012",

month = nov,

doi = "10.1016/j.ajog.2012.08.015",

language = "English (US)",

volume = "207",

pages = "398.e1--398.e8",

journal = "American journal of obstetrics and gynecology",

issn = "0002-9378",

publisher = "Mosby Inc.",

number = "5",

}

TY - JOUR

T1 - Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation

AU - Caritis, Steve N.

AU - Sharma, Shringi

AU - Venkataramanan, Raman

AU - Hankins, Gary D.

AU - Miodovnik, Menachem

AU - Hebert, Mary F.

AU - Umans, Jason G.

AU - Benedetti, Thomas

AU - Mattison, Donald

AU - Zajicek, Anne

AU - Fischer, Dawn

AU - Jackson, Aimee

PY - 2012/11

Y1 - 2012/11

N2 - Objective: The purpose of this study was to estimate pharmacokinetic parameters and to evaluate placental transport of 17-hydroxyprogesterone caproate (17-OHPC) in singleton gestation. Study Design: Sixty-one women who received weekly injections of 17-OHPC underwent 2 pharmacokinetic studies at 20 + 0 to 24 + 6 weeks' gestation (study 1) and 31 + 0 to 34 + 6 weeks' gestation (study 2); daily blood samples were obtained between injections. In 18 women, blood samples were obtained over a 28-day period beyond the last injection (extended study). Maternal and/or cord blood were obtained at delivery. Results: The half-life (median ± SD) of 17-OHPC was 16.2 ± 6 days. Concentrations of 17-OHPC were higher during study 2 than during study 1. Body mass index affected maternal 17-OHPC concentrations. Cord:maternal 17-OHPC concentration ratios averaged 0.2; 17-OHPC was detectible in cord plasma 44 days after the last maternal injection. Conclusion: The apparent half-life of 17-OHPC is long, and pharmacokinetic parameters vary widely between subjects and are affected by maternal body mass index. The drug crosses the placental barrier.

AB - Objective: The purpose of this study was to estimate pharmacokinetic parameters and to evaluate placental transport of 17-hydroxyprogesterone caproate (17-OHPC) in singleton gestation. Study Design: Sixty-one women who received weekly injections of 17-OHPC underwent 2 pharmacokinetic studies at 20 + 0 to 24 + 6 weeks' gestation (study 1) and 31 + 0 to 34 + 6 weeks' gestation (study 2); daily blood samples were obtained between injections. In 18 women, blood samples were obtained over a 28-day period beyond the last injection (extended study). Maternal and/or cord blood were obtained at delivery. Results: The half-life (median ± SD) of 17-OHPC was 16.2 ± 6 days. Concentrations of 17-OHPC were higher during study 2 than during study 1. Body mass index affected maternal 17-OHPC concentrations. Cord:maternal 17-OHPC concentration ratios averaged 0.2; 17-OHPC was detectible in cord plasma 44 days after the last maternal injection. Conclusion: The apparent half-life of 17-OHPC is long, and pharmacokinetic parameters vary widely between subjects and are affected by maternal body mass index. The drug crosses the placental barrier.

KW - cord blood

KW - pharmacokinetics

KW - placenta

KW - preterm birth

UR - http://www.scopus.com/inward/record.url?scp=84868156082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868156082&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2012.08.015

DO - 10.1016/j.ajog.2012.08.015

M3 - Article

C2 - 22967833

AN - SCOPUS:84868156082

SN - 0002-9378

VL - 207

SP - 398.e1-398.e8

JO - American journal of obstetrics and gynecology

JF - American journal of obstetrics and gynecology

IS - 5

ER -

Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this